Contact information
https://orcid.org/0000-0002-4708-2942
IMS-Tetsuya Nakamura Building, Old Road Campus, Roosevelt Dr, Headington, Oxford, OX3 7TY
Dan Jones
PhD
Group Lead - Vaccine Technology
As Group Lead for the Vaccine Technology group, I work alongside Professor Dame Sarah Gilbert and her team to help guide the development of existing and emerging vaccine platforms, with the overarching goal of improving technologies for pandemic preparedness.
I joined the PSI after working at Barinthus Biotherapeutics, where I led projects developing novel viral vector–based vaccine platforms. Before that, I contributed to the advancement of the lentiviral platform at Oxford BioMedica.
Before moving into biotech, I completed postdoctoral fellowships at the Centre for Human Genetics (University of Oxford), studying viral entry into host cells, and at Memorial University of Newfoundland, investigating the molecular mechanisms governing hepatitis C virus assembly and release. I obtained my PhD from the University of Glasgow in 2009.
Recent publications
Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector
Journal article
Coradin T. et al, (2025), Molecular Therapy, 33, 4953 - 4967
MicroRNA-7 mediates cross-talk between metabolic signaling pathways in the liver
Journal article
Singaravelu R. et al, (2018), Scientific Reports, 8
Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material
Journal article
Russell RA. et al, (2017), Cell Reports, 18, 1473 - 1483
Dynamin-2 Stabilizes the HIV-1 Fusion Pore with a Low Oligomeric State
Journal article
Jones DM. et al, (2017), Cell Reports, 18, 443 - 453
Toremifene interacts with and destabilizes the Ebola virus glycoprotein
Journal article
Zhao Y. et al, (2016), Nature, 535, 169 - 172